Vascular endothelial growth inhibitor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(New page: {{PBB|geneid=9966}} {{SI}} {{EH}} ==Overview== '''Vascular endothelial growth inhibitor''' (VEGI) is an anti-angiogenic<ref>[http://www.ihop-net.org/UniPub/iHOP/gs/95120.html Hoffmann,...)
 
m (Bot: HTTP→HTTPS (v470))
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{PBB|geneid=9966}}
{{Infobox_gene}}
{{SI}}
'''Vascular endothelial growth inhibitor''' ('''VEGI'''), also known as '''TNF-like ligand 1A''' ('''TL1A''') and '''TNF superfamily member 15''' ('''TNFSF15'''), is [[protein]] that in humans is encoded by the ''TNFSF15'' [[gene]]. VEGI is an [[anti-angiogenic]] protein.<ref>{{cite journal | vauthors = Hoffmann R, Valencia A | title = A gene network for navigating the literature | journal = Nature Genetics | volume = 36 | issue = 7 | date = Jul 2004 | pmid = 15226743 | doi = 10.1038/ng0704-664 }}</ref> It belongs to [[tumor necrosis factor]] (ligand) superfamily, where it is member 15.<ref name="entrez">{{cite web | title = Entrez Gene: TNFSF15 tumor necrosis factor (ligand) superfamily, member 15| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=9966| accessdate = }}</ref> It is the sole known ligand for [[death receptor 3]],<ref>{{cite journal | vauthors = Wang EC | title = On death receptor 3 and its ligands… | journal = Immunology | volume = 137 | issue = 1 | pages = 114–116 | date = Sep 2012 | pmid = 22612445 | pmc = 3449252 | doi = 10.1111/j.1365-2567.2012.03606.x }}</ref> and it can also be recognized by [[decoy receptor 3]].
{{EH}}
==Overview==
'''Vascular endothelial growth inhibitor''' (VEGI) is an [[anti-angiogenic]]<ref>[http://www.ihop-net.org/UniPub/iHOP/gs/95120.html Hoffmann, R., Valencia, A. A gene network for navigating the literature. Nature Genetics 36, 664 (2004)]</ref> protein. It belongs to [[tumor necrosis factor]] (ligand) superfamily, where it is member 15. '''TNFSF15''' is the human [[gene]] for it.<ref name="entrez">{{cite web | title = Entrez Gene: TNFSF15 tumor necrosis factor (ligand) superfamily, member 15| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=9966| accessdate = }}</ref>


==Gene==
== Function ==
<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
{{PBB_Summary
| section_title =
| summary_text = The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. An additional isoform encoded by an alternatively spliced transcript variant has been reported but the sequence of this transcript has not been determined.<ref name="entrez">{{cite web | title = Entrez Gene: TNFSF15 tumor necrosis factor (ligand) superfamily, member 15| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=9966| accessdate = }}</ref>
}}


==References==
The protein encoded by this gene is a cytokine that belongs to the [[tumor necrosis factor]] (TNF) ligand family. This protein is abundantly expressed in [[endothelial cell]]s, but is not expressed in either [[B cell|B]] or [[T cell]]s. The expression of this protein is inducible by [[TNF-alpha]] and [[IL-1 alpha]]. This cytokine is a ligand for receptor [[TNFRSF25]] (death receptor 3) and TNFRSF6B (decoy receptor 3). It can activate both the [[NF-κB]] and [[MAPK]] signalling pathways, and acts as an [[autocrine]] factor to induce [[apoptosis]] in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an [[angiogenesis]] inhibitor. An additional isoform encoded by an alternatively spliced transcript variant has been reported but the sequence of this transcript has not been determined.<ref name="entrez" />
{{reflist}}
 
==Further reading==
== Clinical relevance ==
{{refbegin | 2}}
 
{{PBB_Further_reading
Several ''TNFSF15'' [[Single-nucleotide polymorphism|SNPs]] have been found to be strongly associated with [[inflammatory bowel disease]].<ref name="pmid17663424">{{cite journal | vauthors = Picornell Y, Mei L, Taylor K, Yang H, Targan SR, Rotter JI | title = TNFSF15 is an ethnic-specific IBD gene | journal = Inflammatory Bowel Diseases | volume = 13 | issue = 11 | pages = 1333–8 | date = Nov 2007 | pmid = 17663424 | pmc = 2552994 | doi = 10.1002/ibd.20223 }}</ref><ref name="pmid16966713">{{cite journal | vauthors = Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T | title = Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease | journal = Gut | volume = 55 | issue = 10 | pages = 1527–8 | date = Oct 2006 | pmid = 16966713 | pmc = 1856432 | doi = 10.1136/gut.2006.100297 }}</ref>
| citations =
 
*{{cite journal  | author=Rubinstein MH |title=A new granulation method for compressed tablets [proceedings]. |journal=J. Pharm. Pharmacol. |volume=28 Suppl |issue=  |pages= 67P |year= 1977 |pmid= 12345 |doi=  }}
== References ==
*{{cite journal  | author=Tan KB, Harrop J, Reddy M, ''et al.'' |title=Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. |journal=Gene |volume=204 |issue= 1-2 |pages= 35–46 |year= 1998 |pmid= 9434163 |doi=10.1016/S0378-1119(97)00509-X  }}
{{reflist|33em}}
*{{cite journal | author=Zhai Y, Ni J, Jiang GW, ''et al.'' |title=VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. |journal=FASEB J. |volume=13 |issue= 1 |pages= 181–9 |year= 1999 |pmid= 9872942 |doi= }}
{{Clear}}
*{{cite journal | author=Yue TL, Ni J, Romanic AM, ''et al.'' |title=TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. |journal=J. Biol. Chem. |volume=274 |issue= 3 |pages= 1479–86 |year= 1999 |pmid= 9880523 |doi=10.1074/jbc.274.3.1479  }}
 
*{{cite journal  | author=Haridas V, Shrivastava A, Su J, ''et al.'' |title=VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. |journal=Oncogene |volume=18 |issue= 47 |pages= 6496–504 |year= 2000 |pmid= 10597252 |doi= 10.1038/sj.onc.1203059 }}
== Further reading ==
*{{cite journal | author=Yu J, Tian S, Metheny-Barlow L, ''et al.'' |title=Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. |journal=Circ. Res. |volume=89 |issue= 12 |pages= 1161–7 |year= 2002 |pmid= 11739281 |doi=10.1161/hh2401.101909 }}
{{refbegin|33em}}
*{{cite journal | author=Migone TS, Zhang J, Luo X, ''et al.'' |title=TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. |journal=Immunity |volume=16 |issue= 3 |pages= 479–92 |year= 2002 |pmid= 11911831 |doi=10.1016/S1074-7613(02)00283-2  }}
* {{cite journal | vauthors = Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A | title = Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells | journal = Gene | volume = 204 | issue = 1-2 | pages = 35–46 | date = Dec 1997 | pmid = 9434163 | doi = 10.1016/s0378-1119(97)00509-x }}
*{{cite journal | author=Chew LJ, Pan H, Yu J, ''et al.'' |title=A novel secreted splice variant of vascular endothelial cell growth inhibitor. |journal=FASEB J. |volume=16 |issue= 7 |pages= 742–4 |year= 2002 |pmid= 11923219 |doi= 10.1096/fj.01-0757fje }}
* {{cite journal | vauthors = Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL | title = VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo | journal = FASEB Journal | volume = 13 | issue = 1 | pages = 181–9 | date = Jan 1999 | pmid = 9872942 | doi =  }}
*{{cite journal | author=Strausberg RL, Feingold EA, Grouse LH, ''et al.'' |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 }}
* {{cite journal | vauthors = Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C, Kumar S, Yu GL, Hart TK, Wang X, Xia Z, DeWolf WE, Feuerstein GZ | title = TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease | journal = The Journal of Biological Chemistry | volume = 274 | issue = 3 | pages = 1479–86 | date = Jan 1999 | pmid = 9880523 | doi = 10.1074/jbc.274.3.1479 }}
*{{cite journal | author=Wen L, Zhuang L, Luo X, Wei P |title=TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. |journal=J. Biol. Chem. |volume=278 |issue= 40 |pages= 39251–8 |year= 2003 |pmid= 12882979 |doi= 10.1074/jbc.M305833200 }}
* {{cite journal | vauthors = Haridas V, Shrivastava A, Su J, Yu GL, Ni J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R, Aggarwal BB | title = VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth | journal = Oncogene | volume = 18 | issue = 47 | pages = 6496–504 | date = Nov 1999 | pmid = 10597252 | doi = 10.1038/sj.onc.1203059 }}
*{{cite journal | author=Bamias G, Martin C, Marini M, ''et al.'' |title=Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. |journal=J. Immunol. |volume=171 |issue= 9 |pages= 4868–74 |year= 2004 |pmid= 14568967 |doi= }}
* {{cite journal | vauthors = Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY | title = Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor | journal = Circulation Research | volume = 89 | issue = 12 | pages = 1161–7 | date = Dec 2001 | pmid = 11739281 | doi = 10.1161/hh2401.101909 }}
*{{cite journal | author=Prehn JL, Mehdizadeh S, Landers CJ, ''et al.'' |title=Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. |journal=Clin. Immunol. |volume=112 |issue= 1 |pages= 66–77 |year= 2004 |pmid= 15207783 |doi= 10.1016/j.clim.2004.02.007 }}
* {{cite journal | vauthors = Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P | title = TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator | journal = Immunity | volume = 16 | issue = 3 | pages = 479–92 | date = Mar 2002 | pmid = 11911831 | doi = 10.1016/S1074-7613(02)00283-2 }}
*{{cite journal | author=Kang YJ, Kim WJ, Bae HU, ''et al.'' |title=Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. |journal=Cytokine |volume=29 |issue= 5 |pages= 229–35 |year= 2005 |pmid= 15760679 |doi= 10.1016/j.cyto.2004.12.001 }}
* {{cite journal | vauthors = Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY | title = A novel secreted splice variant of vascular endothelial cell growth inhibitor | journal = FASEB Journal | volume = 16 | issue = 7 | pages = 742–4 | date = May 2002 | pmid = 11923219 | doi = 10.1096/fj.01-0757fje }}
*{{cite journal | author=Hou W, Medynski D, Wu S, ''et al.'' |title=VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. |journal=Clin. Cancer Res. |volume=11 |issue= 15 |pages= 5595–602 |year= 2006 |pmid= 16061878 |doi= 10.1158/1078-0432.CCR-05-0384 }}
* {{cite journal | vauthors = Wen L, Zhuang L, Luo X, Wei P | title = TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells | journal = The Journal of Biological Chemistry | volume = 278 | issue = 40 | pages = 39251–8 | date = Oct 2003 | pmid = 12882979 | doi = 10.1074/jbc.M305833200 }}
*{{cite journal | author=Yamazaki K, McGovern D, Ragoussis J, ''et al.'' |title=Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. |journal=Hum. Mol. Genet. |volume=14 |issue= 22 |pages= 3499–506 |year= 2006 |pmid= 16221758 |doi= 10.1093/hmg/ddi379 }}
* {{cite journal | vauthors = Bamias G, Martin C, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F | title = Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease | journal = Journal of Immunology | volume = 171 | issue = 9 | pages = 4868–74 | date = Nov 2003 | pmid = 14568967 | doi = 10.4049/jimmunol.171.9.4868 }}
*{{cite journal | author=Yao JJ, Zhang M, Miao XH, ''et al.'' |title=Isoform of vascular endothelial cell growth inhibitor (VEGI72-251) increases interleukin-2 production by activation of T lymphocytes. |journal=Acta Biochim. Biophys. Sin. (Shanghai) |volume=38 |issue= 4 |pages= 249–53 |year= 2006 |pmid= 16604264 |doi=10.1111/j.1745-7270.2006.00155.x  }}
* {{cite journal | vauthors = Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, Targan SR | title = Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation | journal = Clinical Immunology | volume = 112 | issue = 1 | pages = 66–77 | date = Jul 2004 | pmid = 15207783 | doi = 10.1016/j.clim.2004.02.007 }}
*{{cite journal | author=Prehn JL, Thomas LS, Landers CJ, ''et al.'' |title=The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. |journal=J. Immunol. |volume=178 |issue= 7 |pages= 4033–8 |year= 2007 |pmid= 17371957 |doi= }}
* {{cite journal | vauthors = Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, Kwon BS, Lee WH | title = Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis | journal = Cytokine | volume = 29 | issue = 5 | pages = 229–35 | date = Mar 2005 | pmid = 15760679 | doi = 10.1016/j.cyto.2004.12.001 }}
*{{cite journal | author=Cassatella MA, Pereira-da-Silva G, da Silva GP, ''et al.'' |title=Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. |journal=J. Immunol. |volume=178 |issue= 11 |pages= 7325–33 |year= 2007 |pmid= 17513783 |doi= }}
* {{cite journal | vauthors = Hou W, Medynski D, Wu S, Lin X, Li LY | title = VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth | journal = Clinical Cancer Research | volume = 11 | issue = 15 | pages = 5595–602 | date = Aug 2005 | pmid = 16061878 | doi = 10.1158/1078-0432.CCR-05-0384 }}
*{{cite journal | author=Jin T, Guo F, Kim S, ''et al.'' |title=X-ray crystal structure of TNF ligand family member TL1A at 2.1A. |journal=Biochem. Biophys. Res. Commun. |volume=364 |issue= 1 |pages= 1–6 |year= 2007 |pmid= 17935696 |doi= 10.1016/j.bbrc.2007.09.097 }}
* {{cite journal | vauthors = Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y | title = Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease | journal = Human Molecular Genetics | volume = 14 | issue = 22 | pages = 3499–506 | date = Nov 2005 | pmid = 16221758 | doi = 10.1093/hmg/ddi379 }}
}}
* {{cite journal | vauthors = Yao JJ, Zhang M, Miao XH, Zhao P, Zhu SY, Ding H, Qi ZT | title = Isoform of vascular endothelial cell growth inhibitor (VEGI72-251) increases interleukin-2 production by activation of T lymphocytes | journal = Acta Biochimica et Biophysica Sinica | volume = 38 | issue = 4 | pages = 249–53 | date = Apr 2006 | pmid = 16604264 | doi = 10.1111/j.1745-7270.2006.00155.x }}
* {{cite journal | vauthors = Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR | title = The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells | journal = Journal of Immunology | volume = 178 | issue = 7 | pages = 4033–8 | date = Apr 2007 | pmid = 17371957 | doi = 10.4049/jimmunol.178.7.4033 }}
* {{cite journal | vauthors = Cassatella MA, Pereira-da-Silva G, da Silva GP, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A | title = Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis | journal = Journal of Immunology | volume = 178 | issue = 11 | pages = 7325–33 | date = Jun 2007 | pmid = 17513783 | doi = 10.4049/jimmunol.178.11.7325 }}
* {{cite journal | vauthors = Jin T, Guo F, Kim S, Howard A, Zhang YZ | title = X-ray crystal structure of TNF ligand family member TL1A at 2.1A | journal = Biochemical and Biophysical Research Communications | volume = 364 | issue = 1 | pages = 1–6 | date = Dec 2007 | pmid = 17935696 | doi = 10.1016/j.bbrc.2007.09.097 }}
{{refend}}
{{refend}}


{{SIB}}


<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{Cytokine receptor modulators}}
{{PBB_Controls
 
| update_page = yes
[[Category:Cytokines]]
| require_manual_inspection = no
 
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}


{{WH}}
{{gene-9-stub}}
{{WS}}

Latest revision as of 02:13, 27 October 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Vascular endothelial growth inhibitor (VEGI), also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15 (TNFSF15), is protein that in humans is encoded by the TNFSF15 gene. VEGI is an anti-angiogenic protein.[1] It belongs to tumor necrosis factor (ligand) superfamily, where it is member 15.[2] It is the sole known ligand for death receptor 3,[3] and it can also be recognized by decoy receptor 3.

Function

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF-alpha and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 (death receptor 3) and TNFRSF6B (decoy receptor 3). It can activate both the NF-κB and MAPK signalling pathways, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. An additional isoform encoded by an alternatively spliced transcript variant has been reported but the sequence of this transcript has not been determined.[2]

Clinical relevance

Several TNFSF15 SNPs have been found to be strongly associated with inflammatory bowel disease.[4][5]

References

  1. ↑ Hoffmann R, Valencia A (Jul 2004). "A gene network for navigating the literature". Nature Genetics. 36 (7). doi:10.1038/ng0704-664. PMID 15226743.
  2. ↑ 2.0 2.1 "Entrez Gene: TNFSF15 tumor necrosis factor (ligand) superfamily, member 15".
  3. ↑ Wang EC (Sep 2012). "On death receptor 3 and its ligands…". Immunology. 137 (1): 114–116. doi:10.1111/j.1365-2567.2012.03606.x. PMC 3449252. PMID 22612445.
  4. ↑ Picornell Y, Mei L, Taylor K, Yang H, Targan SR, Rotter JI (Nov 2007). "TNFSF15 is an ethnic-specific IBD gene". Inflammatory Bowel Diseases. 13 (11): 1333–8. doi:10.1002/ibd.20223. PMC 2552994. PMID 17663424.
  5. ↑ Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T (Oct 2006). "Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease". Gut. 55 (10): 1527–8. doi:10.1136/gut.2006.100297. PMC 1856432. PMID 16966713.

Further reading

  • Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A (Dec 1997). "Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells". Gene. 204 (1–2): 35–46. doi:10.1016/s0378-1119(97)00509-x. PMID 9434163.
  • Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL (Jan 1999). "VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo". FASEB Journal. 13 (1): 181–9. PMID 9872942.
  • Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C, Kumar S, Yu GL, Hart TK, Wang X, Xia Z, DeWolf WE, Feuerstein GZ (Jan 1999). "TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease". The Journal of Biological Chemistry. 274 (3): 1479–86. doi:10.1074/jbc.274.3.1479. PMID 9880523.
  • Haridas V, Shrivastava A, Su J, Yu GL, Ni J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R, Aggarwal BB (Nov 1999). "VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth". Oncogene. 18 (47): 6496–504. doi:10.1038/sj.onc.1203059. PMID 10597252.
  • Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY (Dec 2001). "Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor". Circulation Research. 89 (12): 1161–7. doi:10.1161/hh2401.101909. PMID 11739281.
  • Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (Mar 2002). "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator". Immunity. 16 (3): 479–92. doi:10.1016/S1074-7613(02)00283-2. PMID 11911831.
  • Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY (May 2002). "A novel secreted splice variant of vascular endothelial cell growth inhibitor". FASEB Journal. 16 (7): 742–4. doi:10.1096/fj.01-0757fje. PMID 11923219.
  • Wen L, Zhuang L, Luo X, Wei P (Oct 2003). "TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells". The Journal of Biological Chemistry. 278 (40): 39251–8. doi:10.1074/jbc.M305833200. PMID 12882979.
  • Bamias G, Martin C, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F (Nov 2003). "Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease". Journal of Immunology. 171 (9): 4868–74. doi:10.4049/jimmunol.171.9.4868. PMID 14568967.
  • Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, Targan SR (Jul 2004). "Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation". Clinical Immunology. 112 (1): 66–77. doi:10.1016/j.clim.2004.02.007. PMID 15207783.
  • Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, Kwon BS, Lee WH (Mar 2005). "Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis". Cytokine. 29 (5): 229–35. doi:10.1016/j.cyto.2004.12.001. PMID 15760679.
  • Hou W, Medynski D, Wu S, Lin X, Li LY (Aug 2005). "VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth". Clinical Cancer Research. 11 (15): 5595–602. doi:10.1158/1078-0432.CCR-05-0384. PMID 16061878.
  • Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y (Nov 2005). "Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease". Human Molecular Genetics. 14 (22): 3499–506. doi:10.1093/hmg/ddi379. PMID 16221758.
  • Yao JJ, Zhang M, Miao XH, Zhao P, Zhu SY, Ding H, Qi ZT (Apr 2006). "Isoform of vascular endothelial cell growth inhibitor (VEGI72-251) increases interleukin-2 production by activation of T lymphocytes". Acta Biochimica et Biophysica Sinica. 38 (4): 249–53. doi:10.1111/j.1745-7270.2006.00155.x. PMID 16604264.
  • Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR (Apr 2007). "The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells". Journal of Immunology. 178 (7): 4033–8. doi:10.4049/jimmunol.178.7.4033. PMID 17371957.
  • Cassatella MA, Pereira-da-Silva G, da Silva GP, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A (Jun 2007). "Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis". Journal of Immunology. 178 (11): 7325–33. doi:10.4049/jimmunol.178.11.7325. PMID 17513783.
  • Jin T, Guo F, Kim S, Howard A, Zhang YZ (Dec 2007). "X-ray crystal structure of TNF ligand family member TL1A at 2.1A". Biochemical and Biophysical Research Communications. 364 (1): 1–6. doi:10.1016/j.bbrc.2007.09.097. PMID 17935696.



Retrieved from "https://www.wikidoc.org/index.php?title=Vascular_endothelial_growth_inhibitor&oldid=1422680"